Ecuador High Vigilance Agencies: IMDRF Recognition Standards under ARCSA-DE-2026-003-DASP

1. Key takeaways

The IMDRF recognition channel sets a dual threshold: Article 31 requires the evidence to come from a high vigilance agency that is also an IMDRF member, and Article 32 requires the device to be commercialized in an IMDRF Management Committee member jurisdiction, registered as a medical device, and classified by ARCSA as class I–IV. Article 3 defines high vigilance agency dynamically by reference to PAHO/WHO designations, and the official text lists no fixed roster of agencies. Eligibility therefore has to be evidenced afresh for each filing rather than assumed from the country of origin of the reference certificate.

2. Legal basis

Substance of the official definition in Article 3: high vigilance agencies (Agencias de alta vigilancia) are regulatory authorities designated by PAHO/WHO as Regional Reference Authorities (Autoridades de Referencia Regional) and agencies regarded by WHO as Strict Regulatory Authorities (Autoridades Reguladoras Estrictas). The definitions of OPS, OMS and IMDRF in the same article and the abbreviation table in Article 4 provide the interpretive frame within which these designations are read.

3. Expert insights

Insight 1: this is the most valuable piece of hidden information in the entire file. Most secondary sources, in Chinese and English alike, describe the recognition scope as a fixed list of FDA, EMA, Health Canada, TGA and ANVISA. The official text instead uses a standards-based definition: PAHO/WHO Regional Reference Authorities plus WHO Strict Regulatory Authorities. The two categories are parallel alternatives; satisfying either one meets the high vigilance agency requirement. Any agency list that circulates in marketing materials is only a snapshot of the current designations.

Insight 2: the consequences of the definitional approach are threefold.

• The list will change: the WHO list of Strict Regulatory Authorities and the PAHO designations of Regional Reference Authorities are updated over time, and the recognition scope moves with them;
• The mode of proof changes: the applicant cannot simply assert that the certificate comes from a given country, but must evidence that the issuing agency currently holds RRA or SRA status;
• The NMPA of China is currently not covered: NMPA has not been listed by WHO as an SRA nor designated by PAHO as an RRA, so Chinese registration certificates cannot serve directly as evidence for the simplified channel.

Insight 3: Article 32(1) contains two sub-conditions that are frequently and wrongly merged. The original wording requires that the device be commercialized in an IMDRF Management Committee member jurisdiction, provided that the registration or authorization obtained was granted as a medical device. Consequently a certificate alone is not enough: there must be (a) actual commercialization in that jurisdiction and (b) a medical device registration status. Neither limb can substitute for the other, and both should be documented in the filing record.

Insight 4: Article 32(2) restates that classification authority remains with ARCSA. Whatever the class assigned in the country of the reference registration, the device is reclassified by ARCSA upon entry into Ecuador. The foreign class can only serve as supporting argumentation. What is recognized is the evidence, not the conclusion. Applicants should therefore prepare an independent classification rationale under the Ecuadorian rules rather than transplanting the foreign class verbatim.

Insight 5: the form of evidence is a registration certificate or its equivalent document. Article 34(b) refers to a registration certificate or its equivalent document. The criteria for recognizing an equivalent document are not detailed in the new regulation and will depend on the implementing instructions issued by ARCSA. Until those instructions appear, applicants relying on equivalent documents should obtain written confirmation or maintain fallback evidence in the form of a full certificate.

Insight 6: Article 20(d) offers a second channel for relying on international documents. Even outside the simplified procedure, companies may cite official documents issued by other international reference regulatory agencies as supporting material for the technical argumentation required by Article 24. This matters for class III and IV dossiers built on reliance strategies, where recognized international assessments can streamline the ARCSA review even under the general procedure.

4. Practical recommendations

1. Verify agency status against the current WHO/PAHO designations and never against a fixed list.
2. Prepare proof-of-status materials: archived links or screenshots of the official WHO SRA or PAHO RRA documentation, each marked with the date of consultation.
3. Prepare commercialization evidence in parallel: sales evidence in an IMDRF Management Committee member jurisdiction, submitted together with the reference certificate.
4. For China-origin products, file through an entity holding qualifying foreign registrations, or hold the evidence through a third-country registered entity.
5. Assemble the 6-item simplified procedure dossier under Article 34, ensuring the power of attorney is legally authenticated (legalizada).

5. Verification checklist

• □ Checked the current WHO SRA or PAHO RRA status of the intended agency
• □ Confirmed that the agency is an IMDRF member
• □ Prepared evidence of commercialization in an IMDRF Management Committee member jurisdiction
• □ Confirmed that the reference registration was granted as a medical device
• □ Completed the independent ARCSA classification
• □ Assembled the 6 items under Article 34 (including the legally authenticated power of attorney)
• □ Archived the agency status evidence together with the consultation dates

Regulatory information verified as of October 29, 2026

Core service areas

1. Global market access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, plus premarket registration pathway planning and filing execution across Latin America, Southeast Asia, the Middle East and other markets.
2. Authorized representative services: EU authorized representative (EC REP), UK responsible person (UK RP), Swiss authorized representative (CH REP), Australia sponsor and US Agent, together with neutral certificate-holder structure design.
3. Quality system compliance: ISO 13485 implementation and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) authoring and remediation.
4. Clinical and evaluation: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why GRZAN

• Local regulatory teams: filings in each target market are executed by locally licensed regulatory professionals and prepared directly in the official language of the market, without secondary translation.
• Neutral holding structure: certificate-holding arrangements that are not tied to any distribution channel, keeping registrations independent of channel partners.
• Regional leverage: a single technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance cost.
• Full lifecycle support: end-to-end service from classification, pathway design and dossier preparation through certificate holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides medical device registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, certificate-holding structure design, official fee and timeline estimation